Abstract
Among the many important physiological functions of the activated vitamin D receptor (VDR) is the signaling of monocytic differentiation, first demonstrated by conversion of malignant myeloid leukemia cells to nonproliferating cells with mature monocyte/macrophage appearance. However, the understanding of how 1, 25-dihydroxyvitamin D3 (1,25D) signals monocytic differentiation is still developing. Recent advances summarized here include the role of the principal mitogen-activated protein kinase (MAPK) pathways, their potential downstream target the CCAAT/enhancer binding protein β (C/EBP β), cell cycle related proteins, and cyclin-dependent kinase 5 (Cdk5) in 1,25D-induced differentiation. The precise steps by which activated VDR signals differentiation are incompletely understood in any of the cell types known to respond to 1,25D. We have focused our studies on HL60 cells, a widely available cell line derived from a patient with promyeloblastic leukemia, with the goal of achieving as clear a picture as possible with the currently available tools. In this model, outlined in Fig. 1, a plausible sequence of events is presented, with the caveats that these are not the only pathways activated by liganded VDR, and that several other pathways, also operative, remain to be convincingly demonstrated. The details of the scheme will be discussed in the sections below.
Keywords: p38 phosphorylation, MEK/ERK pathway, cell cycle, Cdk5/p35 Complex, Leukemia
Current Topics in Medicinal Chemistry
Title: Vitamin D Receptor Signaling of Monocytic Differentiation in Human Leukemia Cells: Role of MAPK Pathways in Transcription Factor Activation
Volume: 6 Issue: 12
Author(s): G. P. Studzinski, E. Garay, R. Patel, J. Zhang and X. Wang
Affiliation:
Keywords: p38 phosphorylation, MEK/ERK pathway, cell cycle, Cdk5/p35 Complex, Leukemia
Abstract: Among the many important physiological functions of the activated vitamin D receptor (VDR) is the signaling of monocytic differentiation, first demonstrated by conversion of malignant myeloid leukemia cells to nonproliferating cells with mature monocyte/macrophage appearance. However, the understanding of how 1, 25-dihydroxyvitamin D3 (1,25D) signals monocytic differentiation is still developing. Recent advances summarized here include the role of the principal mitogen-activated protein kinase (MAPK) pathways, their potential downstream target the CCAAT/enhancer binding protein β (C/EBP β), cell cycle related proteins, and cyclin-dependent kinase 5 (Cdk5) in 1,25D-induced differentiation. The precise steps by which activated VDR signals differentiation are incompletely understood in any of the cell types known to respond to 1,25D. We have focused our studies on HL60 cells, a widely available cell line derived from a patient with promyeloblastic leukemia, with the goal of achieving as clear a picture as possible with the currently available tools. In this model, outlined in Fig. 1, a plausible sequence of events is presented, with the caveats that these are not the only pathways activated by liganded VDR, and that several other pathways, also operative, remain to be convincingly demonstrated. The details of the scheme will be discussed in the sections below.
Export Options
About this article
Cite this article as:
Studzinski P. G., Garay E., Patel R., Zhang J. and Wang X., Vitamin D Receptor Signaling of Monocytic Differentiation in Human Leukemia Cells: Role of MAPK Pathways in Transcription Factor Activation, Current Topics in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/156802606777864935
DOI https://dx.doi.org/10.2174/156802606777864935 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Colon Cancer Therapy: Recent Developments in Nanomedicine to Improve the Efficacy of Conventional Chemotherapeutic Drugs
Anti-Cancer Agents in Medicinal Chemistry DNA Damage Response Pathways and Cell Cycle Checkpoints in Colorectal Cancer: Current Concepts and Future Perspectives for Targeted Treatment
Current Cancer Drug Targets HCV-Related Transformation and New Therapeutic Strategies: An Update
Current Cancer Therapy Reviews Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Measurement of Cdk4 Kinase Activity Using an Affinity Peptide-Tagging Technology
Combinatorial Chemistry & High Throughput Screening Recent Patents on Genes and Gene Sequences Useful for Developing Breast Cancer Detection Systems
Recent Patents on DNA & Gene Sequences Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Computational Analysis of Domains Vulnerable to HPV-16 E6 Oncoprotein and Corresponding Hot Spot Residues
Protein & Peptide Letters Blocking Ca2+ Entry: A Way to Control Cell Proliferation
Current Medicinal Chemistry Inhibitors of Cyclin-Dependent Kinases: Potential Drugs for the Treatment of Neurodegenerative Disorders?
Current Medicinal Chemistry - Central Nervous System Agents A Review of DNA and Histone Methylation Alterations in the New Era of Diagnosis and Treatment of Retinal Diseases
Current Molecular Medicine Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Elucidation of the Molecular Mechanisms of a Salicylhydrazide Class of Compounds by Proteomic Analysis
Current Cancer Drug Targets A Family of Pleiotropically Acting MicroRNAs in Cancer Progression, miR-200: Potential Cancer Therapeutic Targets
Current Pharmaceutical Design A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor
Anti-Cancer Agents in Medicinal Chemistry Carotenoids and Prostate Cancer Risk
Mini-Reviews in Medicinal Chemistry Synthetic Methods of Quinoline Derivatives as Potent Anticancer Agents
Mini-Reviews in Medicinal Chemistry The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry Current Targets for Anticancer Drug Discovery
Current Drug Targets